IMMUNOCORE HOLDINGS PL

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

20 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

13 9 2021 16:30:00 提供 Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

10 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

08 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 8 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

11 8 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

04 6 2021 09:05:00 提供 Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

27 5 2021 16:30:00 提供 Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

18 5 2021 16:10:00 提供 Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2021 Financial Results

12 5 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

28 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

12 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

25 3 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

10 3 2021 19:00:00 提供 Nasdaq GlobeNewswire

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

19 2 2021 07:00:00 提供 Nasdaq GlobeNewswire